transcend semaglutide Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Semaglutide Injection | Starts at

Over time, this can lead to episodes of hypoglycemia, which needs careful management, so monitor your blood sugar levels regularly

During calorie restriction (cutting), more protein is needed to prevent muscle loss (as discussed in the weight loss section)

Quality control concerns with compounded products Compounding pharmacies operate under different regulatory oversight than pharmaceutical manufacturers

Monitor your energy levels and weight to avoid underfueling, and coordinate closely with your prescribing provider. During the first few weeks after switching: You might experience some mild digestive symptoms again, similar to when you first started semaglutide Your healthcare provider may want to monitor your blood sugar more closely if you have diabetes Your weight loss may temporarily slow as your body adjusts to the new medication Just like when you started semaglutide, you'll gradually increase your tirzepatide dose over several months until you reach the target maintenance dose that works best for you